Companies › RHEACELL GmbH & Co. KG
1 active drug program in 3 registered trials: 3 Phase 3; Cardiovascular, Other; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| allo-APZ2-OTS Allogeneic ABCB5-positive dermal mesenchymal stromal cells | ABCB5 | Phase 3 | Epidermolysis Bullosa; Venous Leg Ulcer | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05838092 | allo-APZ2-OTS | Phase 3 | Epidermolysis Bullosa | Other | Aug 2025 |
| NCT05464381 | allo-APZ2-OTS | Phase 3 | Epidermolysis Bullosa | Other | Jan 2027 |
| NCT06489028 | allo-APZ2-OTS | Phase 3 | Venous Leg Ulcer | Cardiovascular | Apr 2027 |
–
Tenax Therapeutics Bracco Diagnostics Getz Pharma Vaderis Therapeutics Huons Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.